中国临床药理学杂志2012，Vol.28Issue(1)：67-71,5.
抗糖尿病新药——I肽基肽酶4抑制剂研究进展
Progress on dipeptidyl peptidase 4 inhibitor, a new class of anti -diabetes drug
摘要
Abstract
Dipeptidyl peptidase 4( DPP4) inhibitor is a kind of new drug to treat type 2 diabetes mellitus (T2DM). It can increase the activity of GLP - 1, ameliorate the metabolism of the glucose and lipid, reduce the apoptosis of the β - cell, and improve the proliferation of the β - cell. DPP4 inhibitor can lower the level of HbA1c and the risk of hypoglycemia and side effect in T2DM patients. DPP4 inhibitor has more advantages than other anti - diabetes drugs because it acts on a new target It will be a useful new class of anti - diabetes drug.关键词
二肽基肽酶4抑制剂/2型糖尿病/β细胞/糖化血红蛋白Key words
dipeptidyl peptidase 4 inhibitor/ type 2 diabetes mellitus/ β-cell/ HbA1c分类
医药卫生引用本文复制引用
刘景龙,环奕,申竹芳..抗糖尿病新药——I肽基肽酶4抑制剂研究进展[J].中国临床药理学杂志,2012,28(1):67-71,5.基金项目
中央级公益性科研院所基本科研业务费专项基金资助项目(2010CHX13) （2010CHX13）
国家科技重大专项创新药物研究开发技术平台建设基金资助项目(2009ZX09301 -003-12-1) （2009ZX09301 -003-12-1）
十一五重大新药创制科技重大专项基金资助项目(2009ZX09303-003) （2009ZX09303-003）
